FINWIRES · TerminalLIVE
FINWIRES

週四交易中,歐洲股票在美國交易,ADR交易量下降

-- 週四上午晚些時候,美國存託憑證(ADR)走低,標普歐洲精選ADR指數下跌0.1%,至1,801.52點,歐洲股市在美國交易。 歐洲大陸方面,領漲的股票包括電信公司諾基亞(NOK)和製藥公司賽諾菲(SNY),分別上漲6.4%和2.5%。緊隨其後的是生物製藥公司argenx(ARGX)和醫療器材製造商EDAP TMS(EDAP),分別上漲0.7%和0.6%。 歐洲大陸方面,領跌的股票包括軟體公司SAP(SAP)和網路廣告公司Criteo(CRTO),分別下跌5%和3.5%。緊隨其後的是網路瀏覽器公司Opera(OPRA)和3D列印機公司Materialise(MTLS),分別下跌3.2%和3.1%。 英國股市漲幅居前的股票包括製藥公司Silence Therapeutics (SLN)和飯店集團洲際酒店集團(IHG),分別上漲4.8%和2.4%。緊隨其後的是生物製藥公司Amarin (AMRN)和電信營運商沃達豐集團(VOD),分別上漲2%和1.6%。 英國和愛爾蘭股市跌幅居前的股票包括生技製藥公司Biodexa Pharmaceuticals (BDRX)和生技公司Trinity Biotech (TRIB),分別下跌6.4%和6.2%。緊隨其後的是軟體公司Endava (DAVA)和生物製藥公司Akari Therapeutics (AKTX),分別下跌6.1%和2.6%。

Related Articles

Research

Research Alert: CFRA Keeps Buy Opinion On Shares Of The Hartford Insurance Group, Inc.

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We trim our 12-month target price by $8 to $155, valuing HIG shares at 11.3x our 2026 operating EPS estimate of $13.75 (cut by $0.45) and at 10.6x our 2027 EPS estimate of $14.65 (cut by $0.30), vs. the shares' one-year average forward multiple of 10.3x and peer average of 13x. Q1 EPS of $3.09 vs. $2.20 a year ago missed our $3.60 estimate and $3.39 consensus view. Operating revenue growth of 6.2% was in line with our 6%-10% forecast, amid 5.3% earned premium growth, 13% higher net investment income, and 7.9% fee revenue growth. Q1 written premium growth of 4% and full-year 2025 growth of 7% bode well for 2026 revenue trends as premiums are earned. Underwriting results improved significantly, with Personal Lines combined ratio improving to 87.7% from 106.1% and underlying combined ratio to 85.0% from 89.7%. Business Insurance combined ratio was stable at 94.8%. Weighing the Q1 EPS miss with HIG's decent top-line growth and discounted valuation to peers, we view the shares as undervalued.

$HIG
Research

Research Alert: CFRA Keeps Strong Buy Opinion On Shares Of Baker Hughes

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We raise our 12-month target price by $14 to $82, reflecting a combination of our sum-of-the-parts (SOTP) and DCF models. For our SOTP model, we presume the oilfield services business (about 50% of BKR's franchise) to be valued at about 10x projected 2027 EBITDA (in line with major peers) and its industrial energy technology business (the other 50%) valued at 14x projected 2027 EBITDA (in line with the peer median). This blended approach, yielding a 12x multiple, implies a value of $73 per share. Meanwhile, our DCF model, using medium-term free cash flow growth of 5% per year, terminal growth of 2.5%, discounted at a WACC of 6.3%, yields intrinsic value of $91 per share. We cut our 2026 EPS estimate by $0.47 to $2.48, but we raise 2027's by $0.07 to $3.24. We acknowledge that the oilfield services business is likely to struggle in 2026 owing to the U.S.-Iran conflict, but the IET business appears quite robust and likely to be a source of both accelerating revenue growth and margins.

$BKR
Research

Research Alert: CFRA Maintains Hold Opinion In Shares Of Wab

CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:We lift our 12-month target to $285 from $275 following WAB's Q1 earnings print, valuing shares at 24.2x our 2027 EPS outlook of $11.76 (revised from $11.46; 2026 EPS estimate up to $10.57 from $10.50), a slight premium to WAB's long-term historical multiple average given structural improvements in earnings quality. While we are cautious on signs of overcapacity in the freight market, an elevated order backlog (12-month sits at over $9 billion), internal initiatives to shore up margins, and potential synergies from M&A activity positions WAB to continue growing earnings at double-digit rates in 2026-2027, in our view. Despite tariff-related cost pressures, WAB has done a commendable job of defending margins via a mix of pricing, lean manufacturing, and pruning of lower-profit operations. Q1 results were mixed but overall positive, in our view. We maintain our Hold recommendation on shares.

$WAB